Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Bacteriology|January 16, 2002
Listeria monocytogenes relA and hpt mutants are impaired in surface-attached growth and virulenceClare M Taylor, Mark Beresford, Harry A S Epton, et al.
BMJ Open|March 30, 2022
'You're kind of left to your own devices': a qualitative focus group study of patients with breast, prostate or blood cancer at a hospital in the South West of England, exploring their engagement with exercise and physical activity during cancer treatment and in the months following standard careSian Karen Smith, Gareth Wiltshire, Frankie F Brown, et al.
The Cochrane Database of Systematic Reviews|January 24, 2018
Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancersTheresa A Lawrie, John T Green, Mark Beresford, et al.
Frontiers in Immunology|February 18, 2021
A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker ProfilingAinhoa Arana Echarri, Mark Beresford, John P Campbell, et al.
The British Journal of Radiology|May 18, 2016
Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?David K Woolf, N Jane Taylor, Andreas Makris, et al.
BJU International|April 29, 2017
Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomyRobert A Huddart, Alison Birtle, Lauren Maynard, et al.
BJC Reports|November 8, 2024
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trialMark Beresford, Angela Casbard, Zoe Hudson, et al.
Oncotarget|September 4, 2015
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancerCarlo Palmieri, Iain Rj Macpherson, Kelvin Yan, et al.
The Lancet. Oncology|October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trialLeisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder CancerThomas Powles, Robert A Huddart, Tony Elliott, et al.
Pageof 3